DBV Technologies S.A. (DBVT) stock

DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 6/30

$11.43−0.45 (-3.79%)

Close on Nov 12, 2026Market cap $718.69MP/E –Yield –

DBV Technologies price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

DBV Technologies's price to sales ratio was 135.2× on Nov 10, 2026, against 63.9× a year earlier. Over the last 5 years it ranged from 1.0× to 162.3×, with a median of 6.2×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 10, 2026	135.2×	+41.6
2025	Dec 31, 2025	93.6×	+88.8
2024	Dec 31, 2024	4.7×	+0.8
2023	Jan 31, 2023	3.9×	−0.6
2022	Dec 30, 2022	4.5×	−2.0
2021	Jan 29, 2021	6.6×	+3.2
2020	Dec 31, 2020	3.4×	–

Where these numbers come from

Parsed from the XBRL in DBV Technologies's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2 reverse split on Jun 7, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing